Basilea Pharmaceutica and Asahi Kasei Therapeutics Advance Pediatric Antifungal Therapy in Japan
Basilea Pharmaceutica, through its partnership with Asahi Kasei Therapeutics, announced on 14 September 2026 the initiation of a Phase‑2, open‑label, multicentre clinical study in Japan aimed at evaluating the safety and pharmacokinetics of the triazole antifungal Cresemba (isavuconazole) in children at high risk for deep mycoses. The investigation represents a pivotal effort to broaden access to a clinically valuable agent for a vulnerable pediatric population that currently lacks robust therapeutic options.
Scientific Rationale
Isavuconazole, the active metabolite of the pro‑drug isavuconazonium sulfate, exerts its antifungal activity by competitively inhibiting the fungal cytochrome P450 14α‑sterol demethylase (CYP51). This blockade impairs ergosterol synthesis, a critical component of fungal cell membranes, thereby disrupting membrane integrity and halting growth of pathogenic species such as Aspergillus, Candida, and Mucorales.
The drug’s pharmacokinetic profile is characterized by a long terminal half‑life (approximately 130 hours) and dose‑dependent absorption that is minimally affected by food intake. Importantly, isavuconazole demonstrates linear kinetics within the clinically relevant dose range and has a low potential for drug–drug interactions compared with other triazoles, owing to its relatively modest CYP3A4 inhibition and negligible CYP2C19 metabolism. These attributes make isavuconazole an attractive candidate for pediatric use, where drug–drug interaction risks are amplified by concomitant chemotherapeutic regimens.
Clinical Context in Pediatrics
Children with haematological malignancies or congenital and acquired immunodeficiencies are at elevated risk for invasive fungal infections (IFIs). Current first‑line agents—such as voriconazole, posaconazole, and liposomal amphotericin B—are limited by toxicity profiles, suboptimal pharmacodynamics in certain age groups, and complex dosing requirements. Consequently, there is a pronounced unmet need for a well‑tolerated, efficacious, and easily administered antifungal in this demographic.
In the United States, Canada, Europe, and China, isavuconazole is already approved for use in children ≥2 years old with invasive aspergillosis or mucormycosis. However, Japanese regulatory authorities have only licensed isavuconazole for adult patients with severe fungal infections, citing the absence of pediatric pharmacokinetic and safety data specific to the Japanese population.
Study Design and Objectives
| Parameter | Detail |
|---|---|
| Phase | 2 |
| Design | Open‑label, multicentre |
| Population | Pediatric patients (≥6 months to 17 years) at risk of deep mycoses |
| Intervention | Standard dosing regimen of isavuconazole (loading dose followed by maintenance dose) |
| Primary Endpoints | Safety profile: incidence and severity of adverse events, laboratory abnormalities, and serious adverse events |
| Secondary Endpoints | Pharmacokinetic parameters (Cmax, AUC, half‑life, clearance) across age strata; preliminary efficacy signals (clinical response, mycological eradication) |
| Control | None (open‑label) |
The absence of a control arm reflects ethical considerations in pediatric oncology settings and the limited alternative antifungal options. The study will employ sparse sampling techniques validated in pediatric pharmacokinetics to minimize blood volume requirements.
Regulatory Pathways
The Japanese Pharmaceuticals and Medical Devices Agency (PMDA) has established a Pediatric Investigation Plan (PIP) framework to accelerate approval of life‑saving therapies for children. By initiating a Phase‑2 study, Basilea and Asahi Kasei are fulfilling a key component of the PMDA’s requirements: generating pediatric pharmacokinetic and safety data that can support a supplemental registration application.
Should the study demonstrate a favorable safety profile and adequate exposure, the data will be leveraged in a Supplemental New Drug Application (SNDA) for pediatric indication. The SNDA will seek to add a “pediatric use” label to the existing adult registration, thereby allowing clinicians nationwide to prescribe isavuconazole in accordance with the evidence generated.
Potential Market Impact
- Expanded Access: Approval in Japan would align the country with global markets where isavuconazole is already available for children, reducing therapeutic disparities.
- Economic Considerations: The drug’s oral formulation and once‑daily dosing could lower hospitalization costs and resource utilization, especially important in pediatric oncology units where inpatient care is intensive.
- Strategic Fit: This initiative dovetails with Basilea’s broader strategy to extend the reach of its existing product portfolio to underserved segments, reinforcing its position as a leader in anti‑infective therapeutics.
Outlook and Caveats
While the Phase‑2 study will provide critical safety and pharmacokinetic data, it will not yield definitive efficacy evidence due to its open‑label nature and limited sample size. Consequently, regulatory approval for pediatric use will likely require post‑marketing commitments or supplemental Phase‑3 data, particularly to demonstrate comparative effectiveness against standard-of-care agents in high‑risk populations.
Moreover, the broader adoption of isavuconazole will hinge on cost‑effectiveness analyses, reimbursement decisions by Japanese health insurance bodies, and clinician acceptance, which are influenced by real‑world outcomes and safety signals observed in ongoing and future studies.
Bottom Line: The initiation of this pediatric Phase‑2 trial represents a scientifically grounded step toward addressing a critical unmet need in Japanese pediatric oncology and immunocompromised populations. By systematically assessing safety and pharmacokinetics in children, Basilea Pharmaceutica and Asahi Kasei Therapeutics are positioning isavuconazole for potential regulatory approval, which could significantly broaden therapeutic options for invasive fungal infections in young patients across Japan.
